Impact of Baseline IgE levels on Exacerbations and Asthma Symptom Control After Omalizumab Initiation

Methods Patients >=12 y/o identified as omalizumab candidates by their treating physicians and with access to treatment through insurance or other funding were enrolled in PROSPERO (n=801); US-based, multicenter, prospective, 48-week observational study of patients with allergic asthma initiating treatment with omalizumab. Conclusions In a real-world setting, patients treated with omalizumab had improved asthma control with decreased asthma exacerbations and increased ACT scores regardless of baseline IgE levels suggesting that although important in omalizumab dosing, IgE may not be a predictive biomarker for response to omalizumab.